New Products

 PITTSBURGH — Mylan on Friday announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its phenytoin chewable tablets USP in the 50 mg strength.

The product is a generic version of Pfizer's Dilantin Chewable Tablets, which are indicated for the control of generalized tonic-clonic (i.e., grand mal) and complex partial (i.e., psychomotor, temporal lobe) seizures, and prevention and treatment of seizures occurring during or following neurosurgery.

NEW YORK — Mustela, a baby care and stretch marks brand, is expanding its line of dermo-pediatrics products with the new Stelatopia Lipid-Replenishing Balm.

CLEVELAND  — American Greetings has announced a new line of children’s birthday cards: The Lost Socks. This new line of cards not only provides a beloved child with a thoughtful and funny greeting, but also gives them a cute and loveable sock puppet as an added birthday gift.

DEERFIELD, Ill. — Walgreens Infusion Services has been selected as a contracted provider of a new injectable medication that helps patients with short bowel syndrome get more — or all — of their nutrients orally, reducing their dependence on intravenous parenteral nutrition, the division announced Wednesday.

 NORTHFIELD, Ill. — Kraft will introduce more than 40 new products in 2013, the company stated. This is the first comprehensive new products launch since Kraft became an independent public company in October. In keeping with the company's initiative to offer consumers good, better and best choices, Kraft is using its iconic brands and successful new platforms to deliver innovation across multiple categories. While some new products are hitting store shelves now, others debut in early 2013.

PALATINE, Ill. — In support of its December launch of the pseudoehedrine product Nexafed, Acura Pharmaceuticals recently kicked off a national e-mail campaign to help drive pharmacists to the Nexafed website with content specifically designed for the pharmacist audience, including infographics, graphic representations of study data and a behind-the-scenes look at Nexafed's abuse-deterrent technology.

CAMBRIDGE, Mass. — The Food and Drug Administration on Monday approved Aegerion Pharmaceuticals' cholesterol drug, Juxtapid.

The drug — an alternative treatment for patients who have a genetic predisposition to high cholesterol — will carry a boxed warning, the strongest level of FDA warning. Juxtapid will be available only through a restricted program due to risk of liver damage.

NEW YORK — Demand for SeroVital-hgh — a proprietary amino acid compound developed by Sierra Research Labs — has spiked in the past month, in part due to recent exposure on news channels like CNN and on news programs like "The Today Show," the company announced last week. To help meet demand, the company on Dec. 21 announced distribution expansion through GNC.